Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must satisfy the following criteria to be enrolled in the study:~1. Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).~2. Subject must have a diagnosis of chronic plaque psoriasis for at least 6 months prior to signing the ICF.~3. Subject must have a diagnosis of moderate or severe psoriasis of the genital area at Screening and Baseline.~4. Subject must have a diagnosis of moderate or severe psoriasis at Screening and Baseline.~5. Subject must have plaque psoriasis (BSA ≥ 1%) in a non-genital area at both Screening and Baseline.~6. Subject must have been inadequately controlled with or intolerant of topical therapy, or topical therapy is inappropriate for the treatment of psoriasis affecting the genital area.~7. Subject must be in good health (except for psoriasis) as judged by the investigator, based on medical history, physical examination, clinical laboratories, and urinalysis.~8. Subject must meet laboratory criteria~Exclusion Criteria:~The presence of any of the following will exclude a subject from enrollment:~1. Subject has any significant medical condition or laboratory abnormality, that would prevent the subject from participating in the study.~2. Subject has any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.~3. Subject has positive Hepatitis B surface antigen or anti-hepatitis C antibody at Screening.~4. Subject has active tuberculosis (TB) or a history of incompletely treated TB.~5. Subject has prior history of suicide attempt at any time in the subject's life time prior to signing the informed consent and randomization, or major psychiatric illness requiring hospitalization within the last 3 years prior to signing the informed consent.~6. Subject has current or planned therapies that may have a possible effect on psoriasis of the body and/or genital area during the course of the treatment phase of the trial~7. Subject had prior treatment with apremilast.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A- Apremilast with Placebo (Type: EXPERIMENTAL): Subjects randomized to the apremilast 30 mg BID treatment group will receive apremilast 30 mg tablets orally twice daily for the first 16 weeks Subjects randomized to the placebo treatment group will receive placebo tablets (identical in appearance to apremilast 30 mg tablets) orally twice daily for the first 16 weeks
- Arm B - Apremilast 30 mg (Type: EXPERIMENTAL): All subjects will receive apremilast 30 mg tablets orally twice daily after the Week 16 Visit through the end of the Apremilast Extension Phase of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).